You can buy or sell CRVS and other stocks, options, ETFs, and crypto commission-free!
Corvus Pharmaceuticals, Inc. Common Stock, also called Corvus Pharmaceuticals, is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. Read More The company focuses on disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.
52 Week High
52 Week Low
Seeking AlphaMar 12
Corvus Pharmaceuticals (CRVS) Presents At Cowen and Company 39th Annual Health Care Conference - Slideshow
The following slide deck was published by Corvus Pharmaceuticals, Inc. in conjunction with this event. 1 26 Click to enlarge Notes:...
Stock Price, News, & Analysis for Corvus Pharmaceuticals
News articles about CRVS stock have been trending somewhat positive recently, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Corvus Pharmaceuticals earned a media sentiment score of 1.1 on InfoTrie's scale. They also assigned media coverage about the compan...
Associated PressMar 7
Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
BURLINGAME, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the fourth quarter and year ended December 31, 2018, and provided a business update. “We continue to make significant progress in the clinic both with CPI-444 and with CPI-006, both as monotherapies and in combination with other agents and...
Expected May 2, After Hours